Avelumab (Bavencio®) accepted for use within NHS Scotland in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma

Approval is based on an RCT which showed avelumab plus axitinib, compared with a vascular endothelial growth factor-targeting tyrosine-kinase inhibitor, improved progression-free survival in adults with advanced renal cell carcinoma.

Scottish Medicines Consortium